| |
Al-In, 2003
|
Al-In, 2005
|
Al-In, 2008
|
Al-In, 2009
|
Coom 2008
|
West, 2003
|
Sponsor
|
Paper
|
Chalmers
|
nhMG
|
nr-hFSH
|
|---|
|
Duijkers, 1997 [46]
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
58
|
7
|
6
|
|
Jansen et al. 1998 [19]
|
0
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
72
|
35
|
54
|
|
Kornilov et al. 1999 [20]
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
67
|
40
|
28
|
|
Serhal et al. 2000 [21]
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
60
|
144
|
94
|
|
Ng et al. 2001 [16]
|
1
|
1
|
1
|
0
|
1
|
1
|
0
|
1
|
56
|
20
|
20
|
|
Strehler et al. 2001 [22]
|
0
|
1
|
1
|
0
|
0
|
1
|
0
|
1
|
67
|
248
|
259
|
|
Westergaard et al. 2001 [17]
|
1
|
1
|
1
|
0
|
1
|
1
|
1
|
1
|
64
|
189
|
190
|
|
Gordon et al. 2001 [15]
|
1
|
1
|
1
|
0
|
1
|
1
|
0
|
1
|
63
|
29
|
39
|
|
European and Israeli Study Group 2002 [14]
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
71
|
357
|
336
|
|
Kilani et al. 2003 [25]
|
0
|
1
|
1
|
1
|
1
|
0
|
1
|
1
|
67
|
50
|
50
|
|
Balasch et al. 2003 [24]
|
0
|
1
|
1
|
0
|
1
|
0
|
1
|
1
|
65
|
25
|
25
|
|
Rashidi et al. 2005 [29]
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
72
|
30
|
30
|
|
Andersen et al. 2006 [5]
|
0
|
0
|
1
|
1
|
1
|
0
|
1
|
1
|
77
|
363
|
368
|
|
Hompes et al. 2008 [28]
|
0
|
0
|
1
|
1
|
0
|
0
|
1
|
1
|
76
|
312
|
317
|
|
Bosch et al. 2008 [27]
|
0
|
0
|
1
|
1
|
0
|
0
|
1
|
1
|
57
|
122
|
126
|
|
Ruvolo et al. 2009 [47]
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
52
|
10
|
19
|
- 16 studies identified from the literature search, compared with previous meta-analyses. The first 6 columns compared the referenced meta-analyses using the following definitions: sponsor, whether or not the study was funded by a pharmaceutical company; paper, whether a peer-reviewed publication or abstract only was available; Chalmers, the Chalmers internal validity mean score [29]. The last two columns are the sample sizes for each study.
